Hospital Pharmacy Europe

FEBRUARY 16, 2024

A new international project aiming to use artificial intelligence (AI) and genomics data to personalise therapies for patients with cardiovascular disease (CVD) has been announced. Personalised medicine is, therefore, the way forward for preventing heart disease, speeding up diagnosis, and monitoring and treating people with CVD. ‘To

Hospitals 52

Hospitals 52

STAT

MAY 20, 2023

An early-stage drug for a heart disease called ATTR-CM showed potential to reverse disease progression, opening up a new way of attacking the condition as existing drugs have been designed to only slow or stall the disease. Continue to STAT+ to read the full story…

107

107

European Pharmaceutical Review

AUGUST 8, 2023

Headline results from Novo Nordisk’s “landmark” SELECT trial in cardiovascular outcomes has demonstrated a 20 percent reduction in major adverse cardiovascular events (MACEs) for semaglutide 2.4mg (Wegovy ® ) compared to a placebo. The SELECT clinical trial enrolled 17,604 overweight or obese adults aged ≥45 years.

Labelling 98

Labelling 98

Pharmaceutical Technology

JUNE 21, 2023

mg tablet) to treat cardiovascular disease. LODOCO is indicated for reducing the risk of stroke, myocardial infarction and cardiovascular death in adults with established atherosclerotic cardiovascular disease (ASCVD) or with multiple risk factors for the disease.

FDA 98

FDA 98

Pharmacy Times

JULY 6, 2022

Pravastatin sodium (Pravachol) is indicated as an adjunctive therapy to diet to lower the risk of myocardial infarction, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident congenital heart disease.

123

123

Hospital Pharmacy Europe

FEBRUARY 1, 2024

Kicking off on 19 March 2024, Clinical Excellence in Cardiovascular Care is a one-day cardiology event for the multidisciplinary team exploring the latest advances in cardiology – and registration is now open. With a whole host of fascinating insights and inspiration for improving patient care, it’s not to be missed.

Hospitals 52

Hospitals Patient Care 52

Pharmaceutical Technology

SEPTEMBER 5, 2022

Soriot said AstraZeneca is particularly interested in oncology, cardiovascular disease, and rare diseases, and taking part in more ‘small to mid-size’ bolt-on acquisitions in the upcoming years. “We Additionally, cardiovascular disease-related acquisitions are not out of the question for AstraZeneca.

FDA 114

FDA Vaccines 114

STAT

JULY 3, 2023

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Novo Nordisk is conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health.

Hospitals 98

Hospitals 98

European Pharmaceutical Review

APRIL 16, 2024

Novartis has released new data from the first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with the rare kidney disease IgA nephropathy (IgAN). The APPLAUSE-IgAN clinical trial is ongoing and only limited interim analysis results can be presented.

FDA 86

FDA 86

Hospital Pharmacy Europe

APRIL 12, 2024

Here, the consultant pharmacist in cardiology and cardiovascular research speaks to Allie Anderson about his innovative services that have enjoyed local, national and international acclaim, and how his own recent experiences as a patient have bolstered his professional work. At their core are medicines optimisation and managing patient risk.

Hospitals 83

Hospitals Documentation Patient Care 83

European Pharmaceutical Review

JULY 26, 2023

The European Commission (EC) has approved Jardiance ® (empagliflozin) for adults with chronic kidney disease (CKD). We celebrate this significant milestone [for this new treatment option] in the field of chronic kidney disease,” commented Daniel Gallego, President of European Kidney Patients’ Federation.

Labelling 95

Labelling Hospitals 95

Hospital Pharmacy Europe

APRIL 19, 2023

Furthermore, the system has the potential to assist with medical education and even clinical decision-making. In the present study, researchers set out to assess ChatGPT’s performance at answering cardiovascular questions and in providing suggestions in case vignettes.

Hospitals 98

Hospitals 98

STAT

DECEMBER 6, 2023

In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Insurance 115

Insurance 115

pharmaphorum

FEBRUARY 21, 2022

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies from AstraZeneca and Johnson & Johnson.

FDA 121

FDA 121

The Checkup by Singlecare

FEBRUARY 5, 2024

Though high cholesterol does not usually cause symptoms, it can lead to high blood pressure, heart disease, stroke, and heart attack if left untreated. Quitting smoking Research shows that the nicotine in tobacco decreases HDL and increases LDL levels, leading to an increased risk of heart disease and high cholesterol.

Packaging 105

Packaging 105

Hospital Pharmacy Europe

FEBRUARY 27, 2023

Despite these known differences, what is less clear, is if this impacts on the incidence of adverse cardiovascular outcomes. Underrepresentation of ethnic and regional minorities in lipid-lowering randomized clinical trials: a systematic review and meta-analysis. years (73% male) were included in the analysis.

Hospitals 98

Hospitals 98

Pharmaceutical Technology

AUGUST 27, 2023

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.

52

52

Pharmaceutical Technology

AUGUST 27, 2023

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.

52

52

pharmaphorum

APRIL 25, 2022

An analysis of 10 clinical trials of digital health interventions targeted at patients recently hospitalised for acute heart failure has found they improve outcomes compared to standard care. with the digital approaches, a reduction of 18%, while cardiovascular mortality was 20% lower (9.6% with usual care to 8.5% days compared to 3.06

Hospitals 139

Hospitals 139

Med Ed 101

APRIL 9, 2023

Bempedoic acid, also known as Nexletol, is a once-daily medication used in patients with increased atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia who are requiring additional LDL-C lowering previously on a maximally tolerated statin therapy along with maintaining a healthy diet.

52

52

European Pharmaceutical Review

NOVEMBER 7, 2022

Results from the EMPA-KIDNEY Phase III clinical trial announced at the American Society of Nephrology (ASN)’s Kidney Week 2022, demonstrated Jardiance ® (empagliflozin) reduced the risk of kidney disease progression or cardiovascular death by 28 percent versus placebo in adults with chronic kidney disease (CKD).

86

86

Board Vitals - Pharmacist

JANUARY 24, 2024

Cardiovascular Disease In 2023, the pass rate for first-time test takers remained level, with 86% of takers passing the exam. Infectious Disease The Infectious Disease board exam saw a slight increase in pass rates, going from 94% in 2022 to 96% in 2023. Don’t become complacent.

101

101

European Pharmaceutical Review

NOVEMBER 21, 2022

SRD-001, the adenovirus associated virus (AAV)-based gene therapy is delivered to cardiac ventricular muscle cells via an intracoronary infusion system (produced by Sardocor, a clinical-stage gene therapy subsidiary of Medera), to increase the protein expression and functional activity of sarcoplasmic reticulum calcium ATPase pump (SERCA2a).

Labelling 131

Labelling FDA 131

The Checkup by Singlecare

JANUARY 22, 2024

It’s why high cholesterol can increase your risk of cardiovascular problems, like high blood pressure, coronary heart disease, or a heart attack. This is the cohort that was often told that drinking a small amount of alcohol could raise good cholesterol levels or even improve cardiovascular health. guidelines for drinking ?

111

111

European Pharmaceutical Review

NOVEMBER 1, 2022

The committee advises that Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib), Rinvoq (upadacitinib) and Xeljanz (tofacitinib), used for chronic inflammatory conditions, should have limited distribution to minimise risk of serious side effects such as cardiovascular diseases, blood clots, cancer and serious infections.

93

93

Hospital Pharmacy Europe

MARCH 1, 2023

They included trials where patients were prescribed aspirin and followed for at least 12 months and the team determined the absolute risks for cardiovascular outcomes, major bleeding and mortality over 5 years. Aspirin With or Without Statin in Individuals Without Atherosclerotic Cardiovascular Disease Across Risk Categories.

Hospitals 95

Hospitals 95

Pharmaceutical Technology

NOVEMBER 6, 2023

StromaForte is under clinical development by Swedish StromaBio and currently in Phase II for Cardiovascular Disease.

40

40

Hospital Pharmacy Europe

AUGUST 31, 2023

Women receiving breast cancer therapy across six clinical centres in Europe will be enrolled in a study to determine whether behavioural and psychological interventions can reduce the cardiac damage from anti-cancer therapies. It is already known that breast cancer survivors have an estimated 32% higher risk of cardiovascular disease.

Hospitals 52

Hospitals 52

European Pharmaceutical Review

OCTOBER 16, 2023

billion, Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences. To date, the small molecule drug has been evaluated in nine clinical trials. In a deal of up to $1.3

59

59

The People's Pharmacy

JUNE 1, 2023

There is also evidence to suggest that influenza vaccines can prevent heart attacks and deaths from cardiovascular disease. What They Discovered About Flu Shots: The authors reviewed five clinical trials involving over 4,000 patients with coronary artery disease. The worse the heart disease, the greater the benefit.

Vaccines 87

Vaccines 87

European Pharmaceutical Review

DECEMBER 5, 2023

Assets Roche will gain rights to through the acquisition “We are encouraged by the clinical data for the lead asset CT-388, which demonstrated substantial weight loss in Phase Ib. These include treatments other benefits, such as preserving muscle mass.

99

99

The Checkup by Singlecare

DECEMBER 21, 2023

It lowers your blood glucose levels, which reduces the risk of diabetic complications such as kidney disease and nerve damage. It is good for assisting with weight loss, improving fertility outcomes, and reducing cardiovascular inflammation—among other things. Read on to find out how and why metformin works to improve health.

Health and Personal Care Stores 105

Health and Personal Care Stores Labelling Dosage FDA 105

pharmaphorum

FEBRUARY 25, 2022

The approval builds upon previously secured indications, including the use of Jardiance to reduce the risk of cardiovascular death plus hospitalisation for heart failure with reduced left ventricular ejection fraction (LVEF), which the FDA greenlighted in 2021. absolute risk reduction, 0.79

FDA 100

FDA 100

pharmaphorum

JANUARY 17, 2023

Late last year, pharmaphorum spoke with AstraZeneca’s Ben Challis, VP and head of translational science and experimental medicine, cardiovascular, renal, and metabolism (CVRM), together with Magnus Jörnten-Karlsson, executive director of Unify. Unify, launched in December 2020, is AstraZeneca’s patient app and clinical trial support tool.

98

98

pharmaphorum

APRIL 23, 2021

The Medicines and Healthcare products Regulatory Agency (MHRA) granted a marketing authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce risk of cardiovascular events in high-risk patients. absolute risk reduction in the first occurrence of major adverse cardiovascular events in comparison to placebo.

98

98

Hospital Pharmacy Europe

NOVEMBER 2, 2022

High C-reactive protein and lipoprotein A levels in percutaneous coronary intervention (PCI) patients worsens cardiovascular outcomes. The risk of a recurrent vascular event in patients with established cardiovascular disease remains even in those with optimal treatment.

Hospitals 52

Hospitals 52

pharmaphorum

JUNE 25, 2021

Amarin’s Craig Granowitz discusses the impact of COVID on cardiovascular disease treatment and explains why there’s still a long way to go till we can truly tackle these diseases. People have come to accept cardiovascular disease and related deaths almost as a part of life – but that doesn’t have to be the case.”.

Communication 99

Communication 99